Skin toxicity related to targeted therapy

Accredited e-learning on skin toxicity related to targeted therapy in GI and liver cancer

This course will help physicians and nurses better understand skin reactions to targeted therapy in GI and liver cancers so that they may prevent, diagnose and manage these dermatologic adverse events and involve a multidisciplinary team to optimise patient care.

Find out more about the programme in this short video:

The e-learning has been developed by an expert faculty:

  • Dr Victor Hugo Fonseca de Jesus, medical oncologist from São Paulo, Brazil (GI CONNECT)
  • Dr Catherine Frenette, hepatologist from San Diego, USA (HCC CONNECT)
  • Natasha Pinheiro, nurse practitioner from New York, USA (GI Nurses CONNECT)
  • Dr Nicole LeBoeuf, dermatologist from Boston, USA

Start your learning journey now:

  • Launch your interactive, multimedia e-learning: https://checkpoint.cor2ed.com
  • Download the educational slide deck summarising the e-learning contents
  • Obtain your own copy of our helpful leaflet to give to your patients

You can claim a number of internationally recognised CME credits by completing this e-learning course. The course is accredited for European CME Credits (ECMECs) and certified for AMA PRA Category 1 CreditsTM as well as American Board of Internal Medicine (ABIM) MOC credit.

Targeted therapies result in more dermatologic adverse events than do non-targeted therapies. Skin toxicity may lead to dosing changes, both physical and psychological discomfort or pain, and increases the risk of total treatment interruption, potentially leading to cancer exacerbation. Pre-emptively addressing and treating potential skin toxicities may improve patients’ quality of life and allow them to remain longer on therapy.

A best practice approach recommends healthcare professionals working as a multidisciplinary team in the prevention, diagnosis, and management of skin toxicities associated with targeted therapy in GI and liver cancers, including colorectal cancer, hepatocellular carcinoma, pancreatic cancer, neuroendocrine tumours, gastric cancer and GIST.

This e-learning will help you understand adverse skin reactions to targeted therapy in GI and liver cancers; know how to prevent and manage skin toxicities associated with targeted therapies in GI and liver cancers; and be able to involve a multidisciplinary team in the prevention, diagnosis, and management of skin toxicities associated with targeted therapy in GI and liver cancers.

This course has been created as a collaboration between GI CONNECT, GI Nurses CONNECT and HCC CONNECT, supported by an independent educational grant from Bayer.